The published evidence is 39 people. One retrospective study at a single hospital followed that many kidney transplant recipients on semaglutide for 13 to 18 months [2]. HbA1c fell from 8.4% to 7.4% and weight from 99.5 kg to 90.7 kg, both significant, with no significant change in markers of graft function.
There is a large, randomized, placebo-controlled answer for chronic kidney disease, and it is a different question. The FLOW trial followed participants with type 2 diabetes and CKD for a median of 3.4 years on weekly semaglutide. A 2026 analysis reports the kidney and survival benefit holding across every stratum of severity, down to advanced disease [1]. Baseline kidney function averaged an eGFR of 47, so these were not mild cases, and the wider picture sits in the pooled kidney outcomes.
Why the FLOW result does not transfer
None of that transfers to someone who has already had a transplant. It is a different population on different medication — immunosuppression that FLOW participants were not taking — and the question after a transplant is not only whether the drug works but whether the graft tolerates it.
Thirty-nine patients, at one center, looked at after the fact, is a reassuring direction rather than an established answer. Nothing in it could detect an uncommon problem, and nothing in it was randomized.
What the wider kidney literature adds
Nothing about transplants, and something about how these results get ranked. An exploratory network meta-analysis of 16 randomized trials put an SGLT2 inhibitor combined with a GLP-1 first on composite renal events, at RR 0.63 (95% CI 0.41–0.97) [3]. An SGLT2 inhibitor alone came in at 0.70 (0.61–0.79).
The combination’s interval nearly touches no effect, and the combined-use category was never randomized, so the strategy that ranked first rests on the weakest evidence in the paper. Its own authors call the finding hypothesis-generating.
A cost model makes the same point about ranking from the money side. In a German model of diabetic nephropathy, tirzepatide produced the most quality-adjusted life years and the lowest net monetary benefit of four options [4], so the best kidney result finished last on value. That is a German modeled lifetime total and not a price anyone pays.
What this means at a checkout
The gap matters where a purchase is made. This desk ranks sellers on published price, and price is the only thing most of them publish — which is the same absence counted in what a good disclosure looks like. A buyer who has had a transplant is making a decision the literature has barely studied, through a form that will not ask about it.
That is not an argument against the drug, and it is not a claim that it is unsafe after a transplant. It is an argument for a nephrologist rather than an intake form. How much clinical follow-up a seller actually provides varies more than the prices do, which is the thread through what patients said when asked.
If cost is what brought you here, the ordinary questions still apply. Whether a rate survives a dose increase is answered for each seller by flat or rising, and what a term commitment actually costs by term and prepay check. They are just not the first question in this case.